anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Advanced age substantially increases the risk for a host of diseases including cardiovascular disease, type 2 diabetes, Alzheimer's disease, and cancer. A major factor that appears to underlie this increased risk with age is reduced capacity to resist oxidative injury or oxidative stress. Therefore, maintaining or increasing the capacity to resist oxidative stress appears critical to the prevention of age-related disease and promotion of successful aging. One potential reason for the lower resistance to oxidative stress with age is a gradual shift in the redox state toward a more oxidized cellular environment potentially disrupting cell-signaling. Nuclear erythroid-2-p45-related factor-2 (Nrf2) is the master regulator of antioxidant defenses. Nrf2 drives expression of a host of genes involved in cellular detoxification and antioxidant defenses. There is strong evidence from animal studies that Nrf2 signaling is reduced with aging and can be at least partially restored with moderate exercise training, however the gap in current knowledge is whether these data do in fact translate to humans. This study will test the following hypotheses in young and older men and women: i) aging is associated with impaired Nrf2 signaling in response to acute exercise and ii) moderate exercise training will improve Nrf2 signaling in older, inactive individuals, and this will increase their resistance to oxidative stress. These hypotheses will be tested by comparing 25 young (18-28y) and 25 older (≥60y) inactive individuals before and after an 8-week exercise intervention (n=15 per age group) and in comparison to non-exercising age-matched control groups (n=10 per age group). Nrf2 signaling will be measured in peripheral blood mononuclear cells (PBMCs) in response to acute exercise and will include gene expression (NRF2, NQO1, HO1, GCLC), protein abundance (NRF2, KEAP1, NQO1, HO1, GCLC) and Nrf2-ARE binding capacity. Resistance to oxidative stress will be measured by plasma F2-isoprostane response to forearm ischemia/reperfusion. The results will increase understanding of the mechanisms of diminished stress resilience with aging and the plasticity of these pathways. This will determine whether targeting Nrf2 signaling will be effective for prevention or treatment of these age-related changes which has an enormous public health impact due to the potential of lowering disease risk and medical costs. An additional significance of this project is creating opportunity for undergraduate and graduate students to become involved in research, an important purpose of the Academic Research Enhancement Award (AREA) program and a mission of Northern Arizona University.
Herein is described a specific amino acid sequence which exhibits specific Ion (bridge) pair arrays enclosed on at least one side by non polar hydrophobic transmembrane segments, as a mechanism used by many infectious agents and a number of cytokine inhibitory factors, such as Interleukin 10 and Prolactin Inhibitory factor and alfa-fetoprotein, to not only undermine the hosts immune defences but to also allow for the infection of target lymphoid tissue. It has been demonstrated that certain vaccines, when inoculated into a host, produced a range of neutralising antibodies but failed to prevent infection when that host is later challenged with live infectious organism. This present patent illustrates that when such vaccine inoculation is coupled with passive immunisation with mono or polyclonal antibodies to these specific amino acid sequences as specificied herein that the host is then capable of overcoming the infectious challenge. Herein is described the therapeutic use of mono or polyclonal antibodies to these said specific sequences as a treatment for Acquired Immune Deficiency Syndrome (AIDS) and other disease states that persist due to the presence of a cytokine inhibitory factor of viral, fungal, bacterial or host origin such as Chronic Fatigue Syndrome where Interleukin 10 mimic molecules are responsible for a multitude of disease symptoms identified as indicative of Myalgic Encephalitis. Herein is described the therapeutic use of mono or polyclonal antibodies to these specific amino acid sequences as a combination therapy with vaccines and anti-viral agents to prevent side effects from certain immune modulation and anti-viral agents (e.g. DHEA and IL-12) which cause enhanced production of Interleukin 10 or AFP mimic molecules during therapy.
INTRODUCTION: Many people experience persistent symptoms for more than 12 weeks following SARS-CoV-2 infection, which is known as post-COVID-19 condition (PCS) or Long COVID (LC). PCS can impair people's quality of life and daily functioning. However, there is a lack of in-depth research exploring the PCS patient journey, as well as gendered aspects of patients' experiences.
METHODS: Nineteen semi-structured qualitative interviews were conducted with people living with PCS in the United Kingdom (13 women, 6 men). Interviews were transcribed verbatim and analysed inductively using reflexive thematic analysis.
RESULTS: Five main themes were identified: 'Symptom dismissal', 'Lack of information and support', 'Life before and after Long COVID', 'Psychological impact' and 'Acceptance'. A shift overtime to self-management of symptoms was evident. These themes represent different stages of patients' PCS journey. Narratives indicated that women highlighted dismissal by healthcare professionals (HCPs), which was not as prominent in men's narratives. In addition, women went into more detail about the psychological impact of PCS compared to men.
CONCLUSION: Women with PCS reported symptom dismissal by HCPs, which may have delayed their diagnosis and negatively affected their well-being. We were not able to explore the experiences of people from non-conforming gender groups. Raising awareness of these issues among HCPs, particularly general practitioners, could improve patient care in PCS.
PATIENT OR PUBLIC CONTRIBUTION: Patient and public involvement consisted of people who took part in the interviews and commented on the themes' interpretation and study conclusions.
The invention relates to a method for preparing polymer-supported organotin compound by using organic magneson and application of the organotin compound. Organic magneson and resin 1-supported trialkyl halogenated tin group are used for preparing solid-phase organotin compound 2. The reaction formula is shown in the description. The resin 1 is resin or silica gel loaded with -SnR2X group. X and X' respectively represent halogens comprising Cl, Br and I. R group represents -(CH2)nCH3, wherein n is equal to 0-6. Solvent represents a solvent comprising tetrahydrofuran (THF), 1, 4-dioxane, glycol dimethyl ether, diethyl ether, tert-butyl methyl ether, N, N-dimethyl amide (DHF), N, N-dimethyl acetamide and N-methyl pyrrolidone (NMP). T DEG C represents a reaction temperature between -55 DEG C and 30 DEG C. R1 represents aryl group, heterocycle, alkenyl or alkyl. According to the invention, there is no need to carry out chemical protection on functional groups for a number of halogenated aromatic compounds with the functional groups; so that not only the preparation cost is reduced but also the preparation difficulty is reduced and the like.
A skin whitening composition containing a puerarin or its derivative is provided to suppress the activation of tyrosinase and inhibit melanogenesis. A skin whitening composition comprises 0.0001-10 weight% of puerarin of the chemical formula 1 or its derivative as an active ingredient. The puerarin is obtained by extracting and purifying from Pueraria lobata Ohwi. The puerarin derivative is denoted by the chemical formula 2. In the chemical formula 2, R is alpha -1,6- glucosyl. The composition has the skin whitening effect by suppressing the expression of TRP-1(tryptophan biosynthesis 1) and TRP-2 genes and suppressing the protein expression of MITF(microphthalmia-associated transcription factor). The composition is used in a form of skin softener, astringent, nutrition skin, eye cream, nutrition cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence, and pack.
The lasting consequences of delirium in children are not well characterized. This study aimed to compare the two-month outcomes in pediatric intensive care unit (PICU) survivors according to the presence of delirium. Post-hoc analysis of a single-center prospective study of mechanically ventilated (invasive ventilation or non-invasive ventilation) children followed at the CHU Sainte-Justine PICU follow-up clinic two months after PICU discharge, between October 2018 and August 2022. Delirium was defined as one or more Cornell Assessment of Pediatric Delirium (CAPD) scores ≥ 9. Primary outcome was survivors' quality of life and secondary outcomes were sleep and posttraumatic stress and anxiety and depression in parents. Multivariable linear and logistic regression models assessed the independent associations between delirium and outcomes while adjusting for age, sex, comorbidity, diagnosis, severity of illness, PICU length of stay, and invasive mechanical ventilation. Of the 179 children included over a 47 month-period, 117 (65.4%) had delirium. Children with delirium were more commonly intubated (91.5% vs. 30.7%, p < 0.001) and had higher PELOD-2 scores (10 vs. 4, p < 0.001). On multivariable analysis, delirium was associated with a decreased quality of life at 2.3 months post discharge (p = 0.03). The severity of the delirium episode (higher scores of CAPD) was associated with a higher likelihood of sleep disturbances (OR 1.13, p = 0.01) and parental anxiety (OR 1.16, p = 0.01), in addition to lower quality of life (p = 0.03).Conclusions: Two months following their PICU stay, children with delirium had a lower quality of life, suggesting a lasting effect of delirium on children and their families.
Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
FIELD: medicine.SUBSTANCE: invention relates to medicine, diagnostics of adenoma of parathyroid glands (PTG), and can be applied in radiodiagnostics, endocrinology, surgery. Multi-phase multispiral computed tomography (MSCT) with X-ray contrast preparation (RC) is carried out at arterial and venous phases of analysis - respectively at 25 and 50 seconds after RC introduction. reading of parameters, analysis of obtained images and pre-operation diagnostics of patient's state are performed. RC is introduced single time, after its introduction physiological solution is introduced intravenously, with introduction of preparations through catheter at rate 4±1 ml/s. Visual and densitometric analysis of obtained images are performed in analysis of obtained images. As analysis parameters determined are: coefficient of radiation attenuation in all formation of the area under examination, suspicious of PTG adenoma. Presence of adenoma is diagnosed with fixation of X-ray radiation attenuation coefficient to +180+200 HU at early arterial phase and detection of not less than 80 HU density reduction at venous stage.EFFECT: method provides improvement, high quality of diagnostics of PTG adenomas due to more accurate fixation of neoplasm location, optimal distribution and retention of contrast substance in the zone of examination in healthy and pathogenic zones, which makes it possible to reduce operation time to 15 minutes instead of 60 minutes, reduce post-operation period from 5 days to 1 day.6 dwg, 4 ex
Relapse after ASCT is an important factor affecting the long-term prognosis of patients with AL amyloidosis. However, the risk factors of relapse are unknown and there are limited studies on treatment outcomes of these patients. We retrospectively reviewed 170 patients with AL amyloidosis who underwent ASCT between 2010 and 2021. Seventy-six patients confirmed as relapse and the median time from ASCT to relapse was 39 months. On multivariate analysis of variables before and after ASCT, lambda restricted, dFLC >30 mg/L pre ASCT, reduced dose melphalan and dFLC >10 mg/L at 6 months after ASCT were independent risk factors for relapse, and achieving CR after induction therapy and renal response after ASCT were protective factors. Most relapsed patients were treated with bortezomib-based regimens (50%) followed by daratumumab-based regimens (22.2%) and other chemotherapy regimens (13.9%). The overall hematological response in evaluable patients was 68.2% with 56.8% achieving CR/VGPR. The median PFS and OS from post-transplant relapse were 25 months and 81 months, respectively. Patients receiving bortezomib or daratumumab showed a better survival compared to other chemotherapy regimens. In conclusion, this study identified independent risk factors of post-transplant relapse and demonstrated the superiority of bortezomib or daratumumab treatment for these patients. CLINICAL TRIAL REGISTRATION: NCT04210791.
This study consists of 3 parts. SAD Part: The participants in the SAD cohorts of the study (Cohort 1 to Cohort 5) will receive a single dose of RSN0402 at 2, 4, 8, 12, or 16 mg dose or placebo via inhalation using a dry powder inhalant. Participants from Cohort 2 will receive a single dose of 150 mg nintedanib soft capsule after 7-day washout period. After completion of Cohort 3, SRC will decide whether to enrol Cohort 4 sequentially or to skip Cohort 4 and enrol Cohort 5 directly based on the safety and PK data collected from the Cohort 1 to Cohort 3. If there are no safety concerns, Cohort 5 will be enrolled after Cohort 3.

MAD Part: The MAD Part consists of 4 cohorts with 8 participants in each cohort. Participants will be randomly assigned to receive RSN0402 (4, 8, 12, or 16 mg) or placebo for 7 days at a ratio of 3:1. In MAD study, the IP will be administered once daily from Day 1 to Day 7. The doses in MAD Part of the study could be adjusted at the discretion of the SRC based on the review of data from the SAD cohorts. The dose regimen in MAD Part may also be adjusted to twice daily or another regimen if there is any concern after SRC review of the available data from SAD cohorts. The adjusted dose and dose regimen cannot exceed the maximum safety daily dose confirmed in the SAD Part.
The invention relates to a dietetic therapy formula for preventing and treating senile dementia. A dietetic therapy product is characterized by comprising the following components in weight: 10-30g of mulberries, 5-15g of fructus alpiniae oxyphyllae, 10-50g of walnut kernels, and 10-150 g of polished round-grained rice. A preparation method of the dietetic therapy product comprises the steps of washing out impurities from the mulberries, the fructus alpiniae oxyphyllae, the walnut kernels and the polished round-grained rice, putting the cleaned mulberries, fructus alpiniae oxyphyllae, walnut kernels and polished round-grained rice into a pot together and cooking by adding 1000ml of water to obtain porridge, for later use. The dietetic therapy product for preventing and treating senile dementia and various pharmaceutical components used in the preparation method have the effects that due to compatible combination, the mulberries, the fructus alpiniae oxyphyllae, the walnut kernels and the polished round-grained rice have the effects of tonifying liver, nourishing kidney, tonifying spleen and benefiting brain. The dietetic therapy product for preventing and treating the senile dementia meets a medicine and food homologous dietetic therapy formula, and is free from any toxic and side effect to long-term use people. A use method is that the cooked porridge is eaten for two times in one day in the morning and evening.
PROBLEM TO BE SOLVED: To obtain a safe melamine production-inhibiting agent containing β-lactoglobulin and not producing side effects. SOLUTION: This agent contains β-lactoglobulin in an amount of at least 10μg/g, preferable 10μg/g to 10mg/g, as an active ingredient. The agent can be prepared in the form of not only a conventional agent for external use, a conventional cosmetic, etc., but also an ointment, a cream, a foundation, a skin lotion, etc. The β-lactoglobulin is obtained from the milk of a mammalian, especially advantageously from cow's milk, and the β-lactoglobulin itself expresses an externally strong melamine production-inhibiting action.  The β- lactoglobulin is obtained e.g. by adding hydrochloric acid to cow's milk, filtering off the precipitated casein, adjusting the pH of the obtained whey, adding a half saturation amount of ammonium sulfate to the adjusted whey to salt out protein, filtering off the protein, saturating the filtrate with ammonium sulfate to recover protein, again dissolving the protein in water, dialyzing the aqueous solution, crystallizing the β-lactoglobulin and subsequently separating the crystals.
It is intended to provide an antigenic protein originating in testis which has an immune induction activity comparable to a glioma antigen and is applicable to the diagnosis and treatment of glioma, a gene encoding the same, etc. A λ phage cDNA library, which is constructed by extracting the whole RNA from testis, synthesizing cDNA, transferring the cDNA into a λ phage vector and thus infecting Escherichia coil, is reacted with serum of a patient suffering from glioma. Using a labeled anti-IgG antibody, positive clones in which the antibody in the serum has reacted are detected. The thus detected positive clones are further screened several times and an antigen is isolated from clones having reactivity with the antibody. Next, serum screening is carried out with the use of the thus isolated antigen, the serum of a patient with glioma, the serum of a normal subject and so on. Thus, an antigenic protein originating in testis which has an immune induction activity comparable to a glioma antigen and is applicable to the diagnosis and treatment of glioma, a gene encoding the same, etc. are prepared.
The overall goal of this study is to clarify the relationship of adiposity with bone development during adolescence, and to explicate the mechanisms that regulate the effect of excess adiposity on bone. In this effort, we will conduct a 2-year longitudinal study in 400 children and adolescents aged 9-15 years. Using the peak adolescent growth period as a model for probing determinants of bone health may allow for a clearer picture of the processes that regulate bone development, as these processes are highly active at this growth stage. Unlike other studies with surrogates for adiposity, we plan to measure total and central adiposity directly, using dual energy X-ray absorptiometry (DXA) and magnetic resonance imaging. Both bone quantity and bone quality, the two principal determinants of bone strength, will be assessed by peripheral quantitative computed tomography (pQCT) at weight-bearing (tibia) and non-weight-bearing (radius) skeletal sites. Peripheral QCT provides 3-dimensional bone measurements that are not confounded by changes in bone size, a significant confounder of most past studies, which have relied on 2-dimensional bone imaging techniques. To identify mechanistic factors, which may explain the effect of adiposity on bone development, we will measure arterial stiffness, endothelial function, and fasting levels of glucose, insulin, lipids, and C-reactive protein (CRP) to assess how vascular dysfunction, insulin resistance, abnormal lipids, and inflammation are related to bone modeling activity, as measured by serum markers of bone formation and resorption. All measurements will be assessed at baseline and after 1 and 2 years of follow-up.
The recovery and prepn. of a zoo-technical agent for use in sheep rearing comprises recovering a natural-biological active ingredient mixt. of aromas specific to the species of animal (i.e. pheromones) by extractively washing out a substrate contg. the pheromones from hair cut from animals of the same sex arranged in the naturally growing direction of the fibres, cleaning the soln. and then sepn. the solvent. The recovery of the substrate contg. the pheromones in its effective condition is carried out by recovering the hair at a characteristic period specific to the species and race. This characteristic period is determined by max values of physiological-biochemical criteria and max. parameter of sexual behaviour of the animals within this period. USE/ADVANTAGE - The pheromones are recovered from living animals and can be made available in their natural composition and in natural amts. at any point in the year, thus enabling the reproduction to be intensified and independent of season after the first insemination and lambing. As the origin of the pheromones is natural and as they are used in natural quantities there is no toxic risk to the animals nor to the workers, nor to those who will consume the animal prods., nor to the environment.
The participants in MT group will receive music therapy 1 day per week for 1 hour with total 12hours in12 consecutive weeks after initial enrollment. Initial evaluation at the first session, including patient's vital sign, consciousness and spirit. The music therapy will consist of therapeutic singing, interpersonal communication, melody intonation therapy and rhythmic hands slapping. During therapeutic singing session, the music therapists will sing a song first and then the patients sing it after them. Interpersonal communication activity will be led by the music therapist and passed on to one patient to another patient. Melody intonation therapy will comprise communication, chatting and read aloud by using melody.
The presently disclosed subject matter is directed to a method of treating cancer, such as (but not limited to) metastatic bladder and breast cancer. The disclosed method comprises using two treatment modalities to synergistically treat primary and secondary tumor cells in a subject. The first element of the method comprises administering a therapeutically effective amount of a plasmonics-active metal nanoparticle to a subject comprising a primary cancer and a distant metastatic site, wherein the nanoparticle concentrates at the primary cancer. The method further comprises exposing the subject to photon radiation at the site of the primary cancer. The second element of the disclosed method comprises administering a therapeutically effective amount of an immune checkpoint modulator to the subject. The synergistic combination provides a rapid, safe, and effective treatment of local and distant lesions, better than each modality alone.
Group of up to 20 patients will be randomly allocated into an experimental group at a 1:1 ratio intervention to controls. The experimental group will receive all of the preliminary outcome screening with the additional 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
The present invention has an object to provide a flaky particulate material giving skin an excellent smoothness, which is free from whitening problem upon use thereof owing to its high transparency. The present invention also has another object to provide a cosmetic composition containing the flaky particulate material. The present invention relates to flaky particulate material, which has an average coefficient of friction is not more than 0.50, and a total light transmittance is not less than 85%. A particle in the flaky particulate material comprises a substrate particle made of one material selected from the group consisting of mica, a synthetic mica, sericite, talc, barium sulfate and aluminum oxide. The present invention provides a flaky particulate material that gives skin excellent smoothness, a natural tone, and a matt appearance. The flaky particulate material of the present invention gives a cosmetic composition which provides great comfort of use, and an excellent appearance.